Roger Perlmutter, Merck
Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
Merck’s Keytruda may not have qualified as a second- or third-line treatment of triple negative breast cancer, but the PD-1 inhibitor is showing promise for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
